Research programme: immunological disorder therapeutics - Kyowa Hakko Kirin/La Jolla Institute
Latest Information Update: 02 Aug 2013
At a glance
- Originator La Jolla Institute for Allergy & Immunology
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 31 Jul 2013 Early research in Immunological disorders in USA (unspecified route)